SCHEMBL21311154

SCHEMBL21311154

Nc1ncnc2c1ncn2C1(O)COC(CCl)C1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 4/20 0.47
▸ ADORA2A P29274 3/20 0.47
▸ SLC28A1 O00337 2/20 0.47
▸ GMPS P49915 1/20 0.47
▸ PI4KA P42356 3/20 0.46
▸ PI4K2B Q8TCG2 3/20 0.46
▸ PI4K2A Q9BTU6 3/20 0.46
▸ PI4KB Q9UBF8 3/20 0.46
▸ AHCY P23526 3/20 0.43
▸ GSK3B P49841 1/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAP3K7 O43318 1/20 0.41
▸ SLC28A2 O43868 1/20 0.41
▸ GAPDH P04406 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ STAT6 P42226 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21311216 0.89 ADORA2A (0.47) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL25521510 0.89 ADORA3 (0.53) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL23025515 0.89 ADORA3 (0.53) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL21311217 0.88 ADORA2A (0.47) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL20097017 0.80 METTL3 (0.39) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL21311195 0.78 EGFR (0.44) AHCYDOT1L
SCHEMBL21311388 0.77 DOT1L (0.41) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL21311194 0.77 PI4KA (0.48) ADORA3ADORA2ASLC28A1GMPSPI4KA
SCHEMBL21311193 0.77 DOT1L (0.38) ADORA3ADORA2ASLC28A1GMPSKMT2A
SCHEMBL21311469 0.76 ADORA2A (0.37) ADORA3ADORA2ASLC28A1GMPSPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 ADORA3 2754/4885ADORA2A 2943/4885SLC28A1 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback